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In previous work we argued that sociologists need to expand our thinking about 
pharmaceuticalization, the process of understanding and/or treating social, behavioral, or 
bodily conditions with pharmaceuticals. The majority of sociological scholarship has 
investigated pharmaceuticalization as a primarily Western process and conceptualized it 
in modern terms (Bell and Figert 2010, 2012a, 2012b). In our view, the work of 
anthropologists and science and technology studies (STS) scholars who decenter the 
West as the starting point for research opens up new avenues for understanding the global 
dynamics of pharmaceuticalization.  We have also argued in favor of adopting a 
postmodern theoretical lens which allows us to understand pharmaceuticalization both as 
a strategy of enhancement by individuals in resource-rich societies and as an exercise of 
power in resource-poor societies and to bring to light its multiple, multidirectional and at 
times apparently contradictory effects.  
In this chapter we expand upon our previous work and focus on one essential part 
of the pharmaceuticalization process: global clinical trials and related ethical and research 
standards. We also consider the role of global clinical trials in reducing public health 
strategies from a broad array of disease prevention efforts to one seeking to improve the 
health of populations with pharmaceuticals. The issues we explore center upon the key 
research and ethical standards for global pharmaceutical development. We define, review 
and problematize the concept of ethical variability and show how it simultaneously 
upholds and disrupts Western ethical guidelines for human subjects research. In doing so, 
we show how global clinical trials contribute to the further pharmaceuticalization of 
public health worldwide with major implications for people’s lives globally. The degree 
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and scope of how people interact with pharmaceuticals throughout the world is uneven, 
because pharmaceuticalization and global clinical trials map onto global patterns of 
inequality. Some human bodies serve as research subjects whereas some bodies are 
pharmaceutical sales targets. Whereas some people in some areas of the world are 
(over)pharmaceuticalized, other people are (under)pharmaceuticalized. We conclude the 
chapter with a discussion of how and why STS perspectives on harmonization and 
variability in ethical and research standards shed light on the study of 
pharmaceuticalization and more broadly on the global dynamics of health inequality.  
 
Conceptual Framing: Medicalization, Biomedicalization and Pharmaceuticalization 
Because studies of pharmaceuticalization have taken shape alongside the 
development of scholarship about medicalization and biomedicalization, we begin with a 
brief overview of these fields. The concept of medicalization was introduced to the 
medical sociology field in the 1970s to understand and look critically at “the involvement 
of medicine in the management of society” (Zola 1972: 488). Medicalization is now 
ubiquitously used in the social and medical sciences and has successfully moved into 
popular culture. One of the most influential definitions of medicalization comes from US 
sociologist Peter Conrad (2005:3) who declares that the essential meaning of the term is 
“defining a problem in medical terms, usually as an illness or disorder, or using a 
medical intervention to treat it” [emphasis in the original].  Medicalization explains a 
process of medical expansion in a modern society. It makes sense of how and why more 
and more conditions are defined and treated medically and increasingly pharmaceutically. 
Current medicalization scholarship has refocused our analytic gaze from the 
power and authority of the medical profession to consider the active participation of 
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individual patient/consumer/users individually and collectively in medicalization 
processes (Brown and Zavestoski 2005; Crossley 2006), resistance to pharmaceuticals 
(Figert 2011; Williams et al. 2011), and the use of medical prescription drugs for 
nonmedical purposes (Williams, Seale et al. 2008). It has also explored new “engines” of 
medicalization including the pharmaceutical industry (Conrad 2005) and technoscience 
(Clarke et al. 2003). Although medicalization is a capacious concept, it cannot fully 
capture the contemporary global dynamics of pharmaceuticals and technoscience. Thus 
scholars have introduced the concepts of biomedicalization, pharmaceuticalization, and 
pharmaceuticalization of public health, which are often more effective than 
medicalization alone in analyzing the nuances and complexities of the development, 
testing, expansion and distribution of pharmaceuticals in the world today (see Abraham 
and Davis (2014) in this volume and Bell and Figert 2012a for a more extensive 
discussion).  
  Whereas the process of medicalization can be conceived of in modern terms of 
engineering, control, and rationalization, the process of biomedicalization can be 
conceived of in postmodern terms of networks, spirals, and complexity. Understanding 
both the definition and effects of biomedicalization helps to make sense of how and why 
more and more conditions are defined and treated medically and pharmaceutically in the 
21st century. Biomedicalization, as established by Clarke and her colleagues, is a concept 
and analytic tool that captures “the increasingly complex, multisited, multidirectional 
processes of medicalization that today are being both extended and reconstituted through 
the emergent social forms and practices of a highly and increasingly technoscientific 
biomedicine” (Clarke et al 2003, 162). One example of this is the application of screening 
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technologies using molecular biomarkers that constitute new categories of people at risk 
and new opportunities for biomedical surveillance and intervention as well as self-
monitoring and regimens of behavior change (Shostak 2010).  
Although feminist scholars and activists in Women’s Health Movements have 
looked critically at the development of the birth control pill and other reproductive 
technologies since the 1970s and social scientists have studied pharmaceuticals and the 
pharmaceutical industry for many years (e.g., Boston Women’s Health Book Collective 
1973; Hartmann 1987; Gabe and Bury 1988), pharmaceuticalization as a unique term was 
introduced by anthropologists (Nichter 1989). A broadly accepted definition of 
pharmaceuticalization by sociologist John Abraham is “the process by which social, 
behavioral or bodily conditions are treated, or deemed to be in need of 
treatment/intervention, with pharmaceuticals by doctors, patients, or both” (Abraham 
2010a: 290). There are complex forces generating the expansion of 
pharmaceuticalization: Big Pharma’s industry control over the science underpinning drug 
development and testing, skillful use of marketing, and “disease mongering;” physicians 
as prescribers, gatekeepers, and “developers of new medicines often in alliance with the 
industry;” affluent publics in consumer-oriented societies who use information 
technology and become “expert patients;” and governments and insurance companies (for 
a discussion of these forces see the chapter by Abraham and Davis in this volume).  
Pharmaceuticalization scholarship builds on and has explicit ties with 
medicalization scholarship, but scholars generally agree that pharmaceuticalization can 
occur without medicalization, and vice versa.  Studies of the pharmaceutical process, like 
those of the medicalization process, typically do so from the perspective of modern social 
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theory. They draw inspiration and logic from the natural sciences, adopt an engineering 
mentality (Lock 2004), trace the drug development and approval process in terms of 
“countervailing powers” (Busfield 2006), and identify pharmaceuticalization as a search 
for control of behavioral, bodily, or social conditions (Bell and Figert 2012a). 
In our work, we show that current research in anthropology provides a useful 
layer of understanding pharmaceuticalization (Bell and Figert 2012a). Whereas 
sociologists primarily study pharmaceuticalization by focusing upon power, economics 
and treatments in the West and the dynamics of the largest pharmaceutical companies 
(often called Big Pharma) and high-income nation states, anthropologists focus primarily 
upon the issues of pharmaceuticals in low or middle-income countries where the political 
economic systems are often post-colonial or post-communist. This focus has allowed 
anthropologists to conceptualize pharmaceuticalization differently and to examine 
political, economic and organizational dynamics that are less visible in the studies by 
sociologists.   
The pharmaceuticalization of public health as outlined by Biehl and others 
suggests that there is both a political and an economic rationality to cutting back on 
disease prevention efforts in favor of a national pharmaceutical distribution policy (Biehl 
2007, Whitmarsh, 2008). From a neoliberal state perspective, it is cheaper and more 
efficient to diagnose and treat diseases pharmaceutically than to prevent them through 
traditional public health measures. The process of pharmaceuticalization and the policy of 
the pharmaceuticalization of public health are key factors in the expansion of the use of 
pharmaceuticals to treat medical and social problems.  These two “strands” of 
pharmaceuticalization theory and research shed light on the uneven and unequal global 
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processes of pharmaceuticalization.  Thus, in the global North, pharmaceuticalization is 
primarily about expanding social and behavioral diagnostic categories and diagnoses, 
while in the global South, pharmaceuticalization is primarily about expanding access to 
medicines and public health or of increasing testing sites for pharmaceutical clinical 
trials.  In the global South, citizens and nongovernmental organizations (NGOs) – often 
in response to the HIV/AIDS epidemic – have mobilized and demanded access to certain 
drugs or treatments.  
The pharmaceuticalization of public health scholarship also brings a postmodern 
framework to understanding pharmaceuticals today.  We use the term “postmodernity” to 
refer to society based on information technology and characterized by interaction, 
contingency, fragmentation, volatility, and hybridity. In postmodern society, boundaries 
are blurred, such as between public/private, government/corporation, expert/lay, 
human/animal, and human/machine.  Postmodern theory assumes that the political 
economic, cultural, organizational, and technoscientific trends and processes of 
pharmaceuticalization are complex and mutually constituted. The pharmaceuticalization 
of public health is manifest in macrostructural changes as well as in new personal 
identities, subjectivities, and configurations by seeking to connect global dynamics 
among states, non-governmental organizations (NGOs), pharmaceutical companies, and 
local communities (see Petryna et al. 2006; Clarke et al. 2010; Bell and Figert 2012a).  
Much work remains to be done in exploring how pharmaceuticalization works 
globally, and we must recalibrate the balance between studies of the global North and 
global South (e.g., Brazil [Biehl 2006, 2007], Barbados [Whitmarsh 2008], India [Sunder 
Rajan 2007, 2012], Thailand, Uganda and South Africa [Petty and Heimer 2011], and 
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Poland [Petryna 2009]). The pharmaceuticalization of public health can be used to make 
sense of dynamics where states with less power and wealth define free access to 
pharmaceuticals as rights of citizenship (and a new subjectivity, pharmaceutical 
citizenship). It can make visible ways that pharmaceuticalization can contribute to the 
creation of new democratic tools for individuals, activist groups, and states. For example, 
participation in clinical trials of pharmaceuticals can be a strategy to gain access to drug 
treatments and medical care and accomplish what people believe to be in their best 
economic and medical interests. For societies with few resources, pharmaceuticalization 
can be a strategy for realizing the rights of citizens and improving population health. Yet 
defining rights of citizenship as access to pharmaceuticals creates new possibilities for 
entering into the grip of biomedical power, forecloses other approaches to improving 
population health and wellbeing, and contributes to the pharmaceuticalization of public 
health. 
Standardization and Global Clinical Trials  
In this section, we show how the global expansion of clinical trials and the global 
standardization of research procedures and ethics foster pharmaceuticalization and the 
pharmaceuticalization of public health. Standardization is the process of constructing 
uniformities across space and time. These uniformities, created by multiple historically 
situated actors, are expressed in standards (Timmermans and Berg 2003). The standards, 
in turn, coordinate people and things in “new configurations” (Timmermans and Epstein 
2010: 83). The standardization of both research procedures and ethics has facilitated the 
proliferation of global clinical trials, the portability of results and the global expansion of 
markets. These standards are expressed in and enforced by international organizations 
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(e.g., the International Conference on Harmonization of Technical Requirements for 
Registration of Pharmaceuticals for Human Use [ICH], the Agreement on Trade Related 
Aspects of Intellectual Property [TRIPS]), regulatory agents of the state (e.g., US Food 
and Drug Administration, Drug Controller-General of India), professional governance 
(e.g., the Declaration of Helsinki), and codes and formal laws (e.g., The Nuremberg 
Code, The Belmont Report). At the same time the development of global clinical trials 
has coordinated people and things into new configurations (e.g., “Contract Research 
Organizations”), and subjectivities (e.g., “treatment naïve populations,” “treatment 
saturated populations” discussed later in this chapter). Increasingly, clinical 
pharmaceutical trials have been privatized by the development of a contract research 
industry (Fisher 2006, 2009). 
While not all clinical trials are conducted with pharmaceuticals, many studies by 
anthropologists and sociologists focus on the expansion of global clinical pharmaceutical 
trials as primary components of pharmaceuticalization (e.g., Petryna, Lakoff and 
Kleinman 2006, Dumit 2012a, Williams, Gabe and Davis 2008). In 2006, more than 2.4 
million Americans participated in clinical trials (Dumit 2012a:18). Since the 1990s, the 
number of international subjects involved in clinical trials – including pharmaceutical 
trials – has grown substantially, from 4000 in 1995 to 400,000 in 1999 (Petryna 
2006:189). Until recently, much of the pharmaceutical and clinical research was 
conducted in the US and Western Europe, but today it is likely to be conducted 
elsewhere. During February 2013, 29,623 clinical trials were actively recruiting study 
participants, and almost half of the trials (49%) were seeking subjects exclusively outside 
the United States (http://www.clinicaltrials.gov/  Feb. 11, 2013).  
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There are multiple, multidirectional reasons that clinical trials are pushed and 
pulled globally. The time between first identification of an active agent with therapeutic 
potential and formal approval for marketing is 10-15 years and each new drug costs $897 
million to develop (Busfield 2006; Petryna et al. 2006: 11).1 Developing countries in 
particular are likely to have fewer regulations and a looser regulatory apparatus for 
enforcing ethical and research standards. They provide cheaper labor and lower 
infrastructure costs, reducing overall expenses of clinical trials by 30 to 50 percent 
(Sunder Rajan 2007: 72). In addition they reduce the time line for clinical testing by 
accelerating subject recruitment and improving the likelihood of showing drug 
effectiveness because their populations are more likely to be pharmaceutically or 
treatment naïve, that is to have little or no previous access to pharmaceuticals and no 
background medications at the time of the trial that might confound results.  
Clinical trials are pushed and pulled globally to reduce time and expense both 
because in the US and Western Europe patients and potential human subjects are 
increasingly skeptical of drug trials and because patients and physicians in Eastern 
Europe, Eurasia and the global South need the resources that pharmaceutical companies 
offer. The global expansion of clinical trials opens the possibility for individuals and 
communities to gain access to medicines otherwise unavailable to them (Biehl 2006, 
Nguyen 2005). The use of these pharmaceutically naïve subjects “creates efficient results, 
free of statistical noise” (Petryna 2007: 37).  
 
Standardizing global research procedures 
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The standardization of clinical trials and research procedures and the actors 
involved in this standardization in the 1990s played an important role in the expansion of 
global clinical trials and pharmaceuticals. Global technical standards specifically for 
pharmaceutical research began to be institutionalized in the 1990s, exemplified by the 
development of Contract Research Organizations (CROs) and the International 
Conference on Harmonization (ICH). CROs create mobile clinical trial environments and 
trial results. CROs are private, for profit companies that implement and manage global 
clinical trials for large multinational pharmaceutical companies. Fisher (2009) reports 
that over 75 percent of clinical drug trials in the US are now conducted in the private 
sector. Since the US is the largest pharmaceutical market in the world and by some recent 
estimates Big Pharma makes two-thirds of its profits in the United States, the process for 
pharmaceutical testing in the US and its legitimation by the US Federal Food and Drug 
Administration (FDA) guide how pharmaceutical companies conduct clinical trials 
outside as well as inside the US (Harris 2013). There are four distinct phases of 
pharmaceutical testing for approval by the FDA. Each phase is designed to build upon the 
others and requires increasing numbers of participants.  If a drug is determined to be safe 
in a small group of healthy volunteers (Phase 1with 20-80 participants) and effective in 
treating the targeted condition (Phase 2 with 100-300 participants), the drug will move to 
Phase 3 which is characterized by a large group of participants (usually between 1,000 
and 3,000 people) to confirm the effectiveness and scrutinize any possible side effects. In 
some cases, a Phase 4 (also called "post-marketing") trial will be conducted. This phase is 
primarily observational and is non-experimental and may explore new uses or dosages, or 
use in new populations. 
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CROs work in and serve as the “middlemen” or service providers (see Fisher, 
2009). In primarily low- and middle- income countries, CROs identify research sites, 
clinics, practitioners and recruit human subjects. International CRO’s are important in the 
process of moving a drug from Phase 2 to Phase 3, because of the need for large numbers 
of participants.  Their main source of revenue comes from conducting clinical trials 
efficiently and cost effectively (Petryna 2006: 38). CROs also help to ensure that clinical 
research complies with accepted technical standards and national and international ethical 
guidelines and thereby makes “data from various international sites portable to and usable 
within the US drug approval process” (Petryna 2011:307).   
From 1992 to 2004 the CRO market grew from $1 billion to $7 billion and by 
2004 there were more than 1000 CROs worldwide. A recent survey of CROs found that 
pharmaceutical companies outsourced a wide variety of functions to CRS from design to 
site selection, study conduct, and medical writing (Getz and Vogel 2009). Sunder Rajan 
(2007) highlights the role that consulting firms, such as A.T. Kearney, play in helping 
Big Pharma find international testing sites. Kearney developed an attractiveness index for 
clinical trials (calculated by evaluating patient availability, cost efficiency, relevant 
expertise, regulatory conditions and national infrastructure) and determined that the most 
favorable pharmaceutical testing sites were China, India and Russia (Bailey et al. 2009: 
57). Sunder Rajan (2012: 332) points out that unlike the pharmaceutical companies for 
which the locus of value lies in the valorized expansion of health, the locus of value for 
CROs is the valorized expansion of pharmaceutical clinical trials.  
The development of the CRO industry occurred concurrently with and was 
fostered by the introduction of guidelines for clinical trials established in 1990 by the 
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International Conference on Harmonization (ICH). The ICH was the product of 
international pharmaceutical regulators from the US, the European Union, Japan and the 
pharmaceutical industry (see http://www.ich.org/about/vision.html).  In effect, the ICH 
established uniform research and technical requirements and standards such as 
randomized controlled trials (RCT) – in which subjects are randomly assigned to either a 
treatment group or a control group – in drug testing. At first the use of these standards 
“made clinical data from international research sites transferable and acceptable to 
regulatory bodies in” the major markets of Europe, Japan, and the United States (Petryna 
2007: 30). Since 2007 the ICH has opened up its process and expanded its reach beyond 
these major markets. For example, representatives of drug regulatory agencies from 
Australia, Brazil, China, Chinese Taipei, Russia, India, Singapore, and South Korea have 
been invited to attend the ICH (http://www.ich.org/). Together CROs and the ICH 
construct uniform standards for global clinical trials across time and space.  
 
Standardizing global research ethics and ethical variability 
The successful expansion of global pharmaceutical research depends on adhering 
to certain established international ethical standards.  At the same time, global expansion 
fosters the transformation of these same ethical standards. Since the 1980s, the global 
dynamics of the pharmaceutical industry have played “an important role in shaping 
contexts in which ethical norms and delineations of human subjects are changing” 
(Petryna 2006: 34). In the common narrative of research ethics, ethical standards for 
clinical trials can be traced to the Nuremberg Code (1947) and the Declaration of 
Helsinki (1964), which provide both a moral framework and an explanation for how and 
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why human subjects need and are protected in ordinary scientific and medical practice 
(Hoeyer 2009). In this section we argue that recent revisions to the Declaration of 
Helsinki have created a new configuration of unethical trials, that global ethical standards 
often produce the impetus, justification and tools for turning healthy populations into 
experimental subjects, and that a modernist frame of understanding cannot account for 
these effects. 
There was no international statement differentiating between legal and illegal 
human experimentation until the Nuremberg Code (a set of ten points related to human 
experimentation targeting Nazi doctors and scientists) was established in 1947 during the 
World War II war crimes tribunal. The voluntary consent of the prospective human 
subject is the bedrock of the Nuremberg Code. The Code requires that all unnecessary 
physical and mental suffering should be avoided, the degree of risk should never exceed 
the benefit which may derive from the tested drug or treatment and the research should be 
conducted by scientifically qualified persons.2 The Nuremberg Code continues to serve 
as a “blueprint for today’s principles that ensure the rights of subjects in medical 
research” (Shuster 1997: 1436) although some scholars have convincingly argued that it 
was frequently ignored by scientists and physicians because it was really only for Nazi 
“barbarians” and not everyday scientists and physicians (Katz, 1992, Rothman, 1991 and 
Hoeyer, 2013).  
 The Declaration of Helsinki,3 established in 1964 by the World Medical 
Association, seeks to guide physicians in research with human subjects, and leaves intact 
physicians’ civil, criminal and ethical responsibilities under the laws of their own 
countries. Katz (1992) argues that in contrast to the Nuremberg Code, in the Declaration 
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of Helsinki concerns over the advancement of science began to overshadow concerns over 
the integrity of person. The Declaration has been amended regularly since 1964 but the 
most controversial amendments have to do with the issues of the use of placebos, 
international testing, informed consent, and access to treatment at a trial’s conclusion. 
Effectively, by establishing that placebo trials are acceptable only when no proven 
treatment already exists, the 1996 and 2000 revisions to the Declaration created a new 
configuration of unethical clinical trials in the US and other countries. In the 1996 revision 
to the Declaration, the idea of a placebo, an inert substance or one containing no 
medication, is introduced for the first time: 
In any medical study, every patient – including those of a control group, if any – 
should be assured of the best proven diagnostic and therapeutic method. This does 
not exclude the use of inert placebo in studies where no proven diagnostic or 
therapeutic method exists (as  quoted in Carlson et al 2004: 698). 
In contrast, the 2000 revision to this paragraph reads: 
The benefits, risks, burdens and effectiveness of a new method should be tested 
against those of the best current prophylactic, diagnostic, and therapeutic 
methods. This does not exclude the use of placebo, or no treatment, in studies 
where no proven prophylactic, diagnostic or therapeutic method exists (as quoted 
in Carlson et al. 2004: 700, emphasis in original). 
The US and the FDA have not recognized these recent amendments to the Declaration 
regarding the preference for testing new pharmaceuticals and vaccines against the best 
current methods instead of against a placebo, arguing that this would inhibit the 
development of good science and efficacious drugs (see Wolinsky 2006).  Pharmaceutical 
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trials funded by the US government and its agencies continue to use placebo testing 
throughout the world.  
 International ethical guidelines for research involving human subjects – such as 
the 1996 and 2000 revisions to the Declaration of Helsinki – are being recast along with 
the movement of clinical trials globally. Revisions concerning the use of placebos in 
pharmaceutical research can be traced a growing concern about international studies of 
maternal-fetal HIV transmission in developing countries (Carlson et al., 2004). In an 
article published in the New England Journal of Medicine, Lurie and Wolfe (1997) 
questioned why studies outside the US sponsored by a US government agency, the 
National Institutes of Health, used a placebo design even though there was already a 
known and effective treatment to prevent maternal-fetal HIV transmission available in 
the US. Supporters of the study design and implementation argued that “local cultural 
variables and deteriorated health services” made placebos acceptable and that it would be 
a “paternalistic imposition” for the US to determine the appropriate design of research in 
regions of such poverty (Petryna 2007: 28-29). Similarly, local and national authorities in 
these regions argued that they should determine research conduct and treatment 
distribution.  
As clinical pharmaceutical trials have become globalized, STS scholars and others 
have examined how enacting ethical standards internationally takes place. Petryna (2007) 
argues that “ethical variability” - the creation of local standards to recruit human subjects 
for clinical and pharmaceutical research – produces the conditions for the exploitation of 
“Third World subjects.” Ethical variability legitimates the modification of ethical 
standards according to the local contexts of clinical trials. It has evolved as a tactic for 
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weighing immediate health benefits or outcomes against protection and safety 
considerations and not as a strategy for being sensitive to those persons asked to enroll in 
clinical pharmaceutical trials (Petryna 2007; Farmer and Campos 2004).  
More generally, participants and clinics always adjust and use workarounds in 
implementing ethical standards. Drawing from their study of HIV treatment and clinical 
trials in the global North (2 US clinics) and South (one each in Thailand, Uganda and 
South Africa), Heimer and colleagues show that in all clinics, both North and South, 
“neither research subjects nor the recruitment and consent process actually live up to the 
ethical ideals as embodied in the institutions of informed consent” (Heimer, 2012: 24). 
When researchers or state agencies try to implement any local or global standards, it is 
inevitable that the practices will include workarounds and adjustments. 
Social scientists have observed repeatedly that the Nuremberg Code, Declaration 
of Helsinki, and similar ethical standards for research assume autonomy and choice of the 
individual “and downplay social and economic constraints on individual agency” 
(Marshall and Koenig 2004: 255; see also Fisher, 2009). The result is that global ethical 
standards often provide the impetus, justification and tools for turning healthy 
populations into experimental subjects. As Angell warned in 1997:  
Research in the Third World looks relatively attractive as it becomes better 
funded and regulations at home become more restrictive. Despite the existence of 
codes requiring that human subjects receive at least the same protection abroad as 
at home, they are still honored partly in the breach. The fact remains that many 
studies are done in the Third World that simply could not be done in the countries 
sponsoring the work. Clinical trials have become a big business, with many of the 
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same imperatives. …Those of us in the research community need to redouble our 
commitment to the highest ethical standards, no matter where the research is 
conducted, and sponsoring agencies need to enforce those standards, not undercut 
them (1997: 849).  
To summarize, on the one hand the construction of a universal standard or ethical 
code of conduct for pharmaceutical clinical trials appears to be “good” or “just” because 
it is sensitive to imbalances of power and money. This interpretation would work within a 
modernist framework. On the other hand, treating all people as equal in a world 
characterized by inequality effectively serves to reinforce that inequality. The 
harmonization of ethical codes or standards for global clinical trials obfuscates the 
reproduction and exacerbation of global inequality. Furthermore all global standards are 
practiced and implemented locally and thus entail local workarounds and adjustments in 
the field. The modernist frame, dominant in sociological accounts of 
pharmaceuticalization, cannot account for all of these practices and effects. A 
postmodern framework for understanding global clinical pharmaceutical trials helps the 
analyst move away from an either/or framing to understand that ethical variability is not 
always bad and standardization is not always good. Both variability and, as we discuss 
next, standardization, can produce different outcomes depending upon local settings and 
histories.  
Disruptions to Standardization?  
In this section we show how standard sociological and modernist conceptual 
frameworks for understanding pharmaceuticalization are simply insufficient to explain 
the expansion of clinical trials to the Global South or how in some respects those in low 
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resourced countries benefit more by participation in these trials than those in high 
resourced countries. We address the question of how an understanding of standards and 
rules sheds light on the conceptualization and processes of global pharmaceuticalization 
and the pharmaceuticalization of public health, and we use work on the expansion of 
pharmaceutical clinical trials in India by Sunder Rajan to illustrate our argument (Sunder 
Rajan 2005, 2007, 2012). 
As discussed above, with the expansion of the number of clinical trials, the need 
for human subjects increases, and trials are more and more likely to be conducted in the 
global South with the goal of producing portable results. One reason given for this is that 
these countries are seen as having  fewer regulations and a looser regulatory apparatus 
(Petryna, 2009). Since the 1990s, India has become incorporated into the globalized drug 
development sector. In his study of global pharmaceutical economies, Sunder Rajan 
(2007, 2012) contests the assumptions that ethical standards are “stricter” in the West. In 
2005 India converted its guidelines for informed consent into laws (Schedule Y) and is 
now the only country in the world “where the violation of good clinical practice is a 
criminal rather than a civil offence” (Sunder Rajan 2007: 74). Indeed, Schedule Y 
focuses on ways of insuring informed consent from subjects who are poor and illiterate.  
In many ways, this means that local ethical standards in India are especially tight, and 
global harmonization could diminish the possibility of developing local standards such as 
these. On the surface, the informed consent process in India provides potential 
experimental subjects with the choice to freely participate or not participate in clinical 
pharmaceutical trials. And yet, although subjects may freely give consent to participate in 
clinical trials, their access to pharmaceuticals ends along with the end of the trials. 
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Experimental subjects are still exploited, or in Sunder Rajan’s terms “merely risked” 
because for this population, clinical experimentation is not linked to the benefit of 
subsequent therapeutic access.  
The harmonization of ethical standards provides the conditions for continued 
global pharmaceutical and economic inequality. In India, the apparatus of clinical trials 
simultaneously accepts Western bioethics standards of informed consent and rigorously 
applies them so its research results can travel. At the same time, its population will bear 
the burden without the benefit of research results.  In its careful attempt to adhere to 
global (universal) standards, India creates conditions for the exploitation of Indian bodies 
(and by implication of Third World subjects more generally) because of the real 
economic rewards and the potential for further inclusion in the global pharmaceutical 
economy.  
In the US and most of the world, there is less attention to the ethics of how 
poverty and specific forms of indebtedness shape consent and decisions in 
pharmaceutically naïve populations4 or whether the burden of research is balanced with 
tangible therapeutic benefits after completion of trials (Fisher, 2009).  Advocacy groups 
have learned to fight for access to pharmaceuticals for citizens in the global south (as 
they did successfully in Brazil) (see Biehl 2004, 2007) and for the importation of more 
affordable generic versions of medicines from foreign manufacturers, as Brazil, 
Argentina and South Africa have done for AIDS medicines (WHO Drug Information v. 
19, no. 3 2005, Access to Medicines).5 One way that pharmaceutical companies respond 
to such activism and pressure is by providing therapeutic access through their 
compassionate use programs “which make the drugs tested in Phase 3 trials available to 
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the sick volunteers for a fixed period of time after completion of the trial” (Sunder Rajan 
2007: 79).  
The dynamics of clinical pharmaceutical trials in India, Barbados and Brazil are 
representative of new forms of an international bioeconomy in which nations, the 
pharmaceutical industry and other corporate actors work to create global experimental 
sites. In this new phase of capitalism, clinical pharmaceutical trials establish places where 
experimental subject populations exchange human bodies for payment in the form of cash 
or access to treatment (Sunder Rajan 2006, Dumit, 2012a).  In this context, the problem 
of the exploitation of third world “merely risked” subject populations is not the result of 
the harmonization of standards—either looser standards pulling clinical trials to the 
global South or tighter standards protecting experimental subjects in the global South—
but reflects the reorganization and reconceptualization of global capital in relation to “life 
itself” since the 1980s.  
New Configurations 
Although the global expansion of clinical trials works unevenly throughout the 
world, there is some evidence that in some respects physical sites of the new bioeconomy 
such as health or pharmaceutical clinics in "poor" countries benefit more from these trials 
than do clinics in "rich" countries.  Thus, in a study of clinical trials in countries at 
varying levels of development – the US, South Africa, Thailand and Uganda – Petty and 
Heimer (2011) and Heimer (2012) show that global HIV research can be more beneficial 
to countries in the Global South than to the US. Clinics reconfigure their local practices 
of care and treatment to bring them in line with ICH standards: to produce accurate, 
complete, and verifiable study data and to ensure “that the rights and well-being of 
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human subjects are protected” (Petty and Heimer 2011: 350). These reconfigurations 
include upgrading laboratory facilities to be able to do the complicated tests required by 
clinical trials and using laboratory equipment in study-specific ways to produce 
standardized results. The new configurations vary depending on clinics’ existing 
resources, routines, and relationships. In poorer countries, where equipment is often in 
short supply funders often pay to improve laboratory facilities so clinics can participate in 
research (Petty and Heimer 2011: 342). Once laboratory facilities are upgraded, clinics in 
poorer countries can employ them in both research and treatment. However, because 
materials are less easily repaired, replenished, or replaced, “the overall effect of altering 
the material environment in poorer countries is likely to be modest unless the flow of 
funds is very stable” (Petty and Heimer 2001: 357). By contrast, in richer countries, 
research-provided technologies duplicate already available medical equipment and doing 
the research has a less beneficial effect.   
Clinical pharmaceutical trial participation can also reshape the clinics in ways that 
smooth the way for their later adoption of clinical research findings. The everyday 
actions and results of introducing new jobs, technologies, and standard operating 
procedures for clinical trials is as important to changing medical practice as is the 
influence of subsequent research results. Petty and Heimer (2011) identified three types 
of practices that are changed in the doing of clinical research. The introduction of new 
research-mandated tools alters the material environment, the introduction of new and/or 
retrained staff reorganizes staff relationships in the clinics, and the adoption of research 
practices changes clinic priorities. In other words, conducting clinical research is not just 
a means of testing new treatments that subsequently change medical practice. The new 
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routines for clinical trials change clinic practices so that new therapies will fit local 
conditions and can be translated into medical care (Petty and Heimer 2011).  
In the process of conducting clinical trials, standardization of actions and practices for 
doing the research reshapes the clinics and gives further agency and sometimes 
bargaining power to the clinic staff to advocate for their patients.  
In reconfiguring their local practices in order to participate in global clinical trials, 
Petty and Heimer (2011) found that clinics in the US and the global South fostered a 
pharmaceutical approach to public health that ultimately necessitated and created reliance 
upon technoscience and biomedicine beyond money and supplies. More generally, 
participation in pharmaceutical clinical trials creates regimes of practice and enforces 
ways of thinking and action that focus on pharmaceutical solutions. It forecloses other 
ways of thinking about and treating public health problems. While providing certain 
kinds of benefits to resource poor countries, the pharmaceuticalization of public health 
projects (vaccines, pharmaceutical testing or treatments) excludes cheaper and more 
effective ways to treat the health of the general population. When clinics change how 
they work and think about the way to treat patients in adjusting to pharmaceutical trials, 
they narrow the gaze and focus to one that concludes pharmaceuticals are the ultimate 
solution to improving public health. This is especially problematic in states with fewer 
resources because it ultimately narrows the options to more technological and capital 
intensive solutions.  
Conclusion 
In this chapter we have argued that global research and ethical standards of 
pharmaceutical development – especially in global clinical trials—are institutionalized, 
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disrupted and/or shaped by nation states and international bodies, local and global 
cultures, and multinational pharmaceutical firms.  The standard pharmaceuticalization 
and modernist framework uses one of two possible narratives about why and how clinical 
trials and ethical practices have become standardized. In the first narrative, the institution 
of medicine in conjunction with international regulatory bodies successfully developed 
and adopted scientific and ethical frameworks for the conduct of clinical trials globally. 
The result is better, well-designed, portable, and ethical scientific research and 
pharmaceutical products. The second explanation suggests an alternative result, that 
global bodies are being exploited by the capitalistic expansion of pharmaceutical 
companies into the global South in the pursuit of cheaper trials and an undermedicalized 
surplus army of available bodies.  
But neither of these modernist frames fully captures what is going on with global 
pharmaceutical trials. Ultimately, the outcomes of the clinical trial process internationally 
do not fit standard modernist narratives of either exploitation or the ethical advance of 
scientific research. A modern perspective on global clinical trials employs an either/or 
analysis. Global clinical trials can also be seen through a postmodern framework that 
captures the uneven and contradictory character of pharmaceutical trials occurring 
throughout the world.  We show that bodies used in clinical trials may or may not ever 
benefit from pharmaceutical development and may or may not be exploited during and 
after the trials conclude.  A postmodern perspective enables a more subtle analysis: 
pharmaceutical and clinical trial innovations are made possible by and at the same time 
foster major shifts in the global political economy. This ambiguity is especially apparent 
in the pharmaceuticalization process. Global pharmaceutical trials and ethical research 
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standardization are complex, global, and multi-sited and involve remaking the technical, 
organizational, and institutional infrastructures of the life sciences and biomedicine.  The 
pharmaceutical transformation of life and approach to public health is associated with a 
new, postmodern, era in medicine and society more broadly.  
  To support our argument, we analyzed two cases: Sunder Rajan’s study of clinical 
trials in India and Petty and Heimer’s study of global clinical research in HIV clinics. 
Both of these cases explain how local circumstances help to make sense of 
pharmaceuticalization and the pharmaceuticalization of public health and both cases are 
better explained by a more postmodern than a modern frame. Sunder Rajan shows that 
the particular history of the pharmaceutical industry in India, Indian CROs, and labor 
exploitation, are explanatory "forces" that have led to India's desire to be a location for 
clinical trials. In spite of the fact that most Indians may not benefit directly from 
pharmaceutical research, some poor and illiterate Indians do gain access to clinical trials 
after informed consent is carefully administered to them. Using Sunder Rajan’s case of 
India, we conclude that a modernist explanation of either economic exploitation or 
benefit does not go far enough.  
In the second case we show that the global expansion of clinical trials works 
unevenly throughout the world and further that in some respects clinics in "poorer" 
countries benefit more from these trials than do clinics in "richer" countries. For example, 
Petty and Heimer document how an unintended consequence of participating in global 
clinical HIV trials for those in poor countries is the reconfiguration of their organizational 
and medical practices. An additional consequence is the pharmaceuticalization of public 
health even though it may be a more expensive strategy.  Through their participation in 
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clinical trials, clinics create a regulatory, clinical and institutional apparatus that fosters a 
pharmaceutical approach to HIV. As they write: “… the costs of new pharmaceuticals 
can easily overwhelm the healthcare systems of poor countries, when investing in the 
lower-end of healthcare would surely be wiser” (Petty and Heimer 2011: 357). Public 
health becomes pharmaceuticalized with significantly different procedures and 
consequences. The contradictions, reversals, and production of new subjectivities such as 
pharmaceutical citizenship or reconfigured clinics are better explained by a postmodern 
than a modern theory of pharmaceuticals. 
Finally, both of these cases show that while in theory the call for global ethical 
research standards appears to be a modern and scientific way forward, in reality the 
implementation of these standards is not “standard” and not always beneficial to clinics 
and patients in poor countries. Clinics or countries encourage and produce 
“workarounds” in their efforts to conform to standards. Distinctions such as ethical 
variability versus standardization—and the modernist assumptions and interpretations of 
their effects--fail to capture some of the surprising ways in which standards and 
variability shape the experiences of people in very different parts of the world who are 
part of a global pharmaceutical system, and thus modernist approaches do not help us 
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Notes 
                                                 
1According to the Pharmaceutical Research and Manufacturers of America (PHRMA), 
only “one of every 10,000 potential medicines investigated by America’s research-based 
pharmaceutical companies makes it through the research and development and is 
approved for patient use by the United States Food and Drug Administration” and on 
average it takes 15 years of research and development and more than $800 million for 
each pharmaceutical that makes it to the market. 
http://www.phrma.org/innovation/  PhRMA “Innovation” Retrieved Sept. 12, 2007 
2 See Trials of War Criminals before the Nuremberg Military Tribunals under Control 
Council Law No. 10", Vol. 2, pp. 181-182. Washington, D.C.: U.S. Government Printing 
Office, 1949. 
3 See the World Medical Association for the most current version of the Declaration 
http://www.wma.net/en/10home/index.html 
4 For example, in Mumbai, India, most of the subjects for clinical trials were recruited 
from among unemployed textile workers who had lost their jobs after the collapse of the 
textile industry in the 1980s and 1990s (Sunder Rajan 2005). 
5 The Indian state has just begun to do this by issuing compulsory licenses for producing 
generic versions of patented medicines (see Harris, NYT April 1, 2013). 
